Inhibitors of mammalian targets of rapamycin (mTOR) or vascular endothelial growth factor receptor (VEGFR) will be applied clinically for the treatment of renal cell carcinomas with the aim of depriving the cells of nutrition [12], [13]. Here, MTOR is linked to renal cell carcinoma.